{"chain_id": "chain_000000", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5948914", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5948914, is the following pharmacogenomic claim supported or contradicted: Genotypes GT + TT are not associated with overall survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "Looking at the paper, I need to identify which SNP might correspond to genotypes described as GT+TT vs GG.\n\nThe paper examines six candidate SNPs. Looking at the SNPs with C>T variants:\n\n- **SLC29A3 S158F** (c.473C>T, rs780668): Genotypes are CC vs CT/TT. Patients with CT/TT had significantly longer median OS (17.64 months) compared to CC (8.43 months), with adjusted P = 0.017. This SNP **is** associated with overall survival.\n\n- **POLR2A N764K** (c.2292C>T, rs2228130): Genotypes CC vs CT. No significant association with OS (P = 0.734).\n\n- **HELB T980I**, **CTDP1 T221M**, **NT5C2 D549E**: None showed significant OS associations.\n\nThe question uses \"G\" and \"T\" alleles rather than \"C\" and \"T.\" This likely refers to the same SNPs but reported on the complementary strand (G being"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**\n\nThe study performs survival analysis (Kaplan-Meier, log-rank tests) and hematologic toxicity analyses (chi-squared tests, logistic regression) to correlate SNP genotypes with patient outcomes (overall survival, progression-free survival, and grade 3/4 toxicities) in a clinical cohort of NSCLC patients treated with gemcitabine-based chemotherapy. This represents a clinical association study, not a functional assay measuring direct biological or biochemical effects of the variants."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2231142 and gemcitabine in Disease:Non-Small Cell Lung Carcinoma (PMCID PMC5948914), what p-value was reported for this association?", "answer": "= 0.080", "response": "The paper reports multiple p-values for rs2231142 (ABCG2 Q141K) depending on the outcome measured:\n\n- **Progression-Free Survival (PFS):** adjusted P = **0.007** (multivariate Cox regression); univariate P = 0.003\n- **Overall Survival (OS):** adjusted P = 0.080 (multivariate); univariate P = 0.017\n- **Grade 3/4 Thrombocytopenia:** adjusted P = **0.008** (multivariate logistic regression); univariate P = 0.015\n- **Grade 3/4 Neutropenia:** P = 0.113 (not significant)\n\nThe most prominently significant associations for rs2231142 were with **PFS (adjusted P = 0.007)** and **grade 3/4 thrombocytopenia (adjusted P = 0.008)**."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "**True**\n\nThe associations for rs2231142 (ABCG2 Q141K) with progression-free survival (adjusted P = 0.007) and grade 3/4 thrombocytopenia (adjusted P = 0.008) are both below the alpha = 0.05 threshold, making them statistically significant."}]}
{"chain_id": "chain_000001", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC11732454", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11732454, is the following pharmacogenomic claim supported or contradicted: HLA-A *31:03 is associated with decreased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine, lamotrigine or phenytoin. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Contradicted.**\n\nThe paper found that HLA-A*31:03 was present in 2 SJS patients and 0 controls (Table 5), with a p-value of 0.04, suggesting it was associated with SJS in AED-treated patients (though it did not survive Bonferroni correction). The allele was found only in the SJS case group, not in the control group, indicating an association with *increased* (not decreased) risk of SJS. The claim that it is associated with a *decreased* likelihood of SJS is therefore contradicted by the study's findings."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of HLA-A*31:03 and carbamazepine, lamotrigine, phenytoin in Toxicity (PMCID PMC11732454), what confidence interval was reported?", "answer": "0.13\u20130.27", "response": "The paper does not report a specific confidence interval for HLA-A*31:03 in relation to SJS specifically. However, from **Table 2** (the overall SCARs analysis for HLA-A*31:03), the reported 95% confidence interval was **0.27\u20130.43**.\n\nNo separate confidence interval was provided for HLA-A*31:03 broken down by individual drug (carbamazepine, lamotrigine, or phenytoin)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "**True**\n\nThe reported 95% confidence interval of **0.27\u20130.43** does not include 1.0, so it excludes the null value."}]}
{"chain_id": "chain_000002", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4640545", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4640545, is the following pharmacogenomic claim supported or contradicted: Genotype CC is not associated with metabolism of carbamazepine in people with Epilepsy as compared to genotypes CT + TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Based on the paper, the ABCB1 3435C>T SNP (where CC, CT, and TT are the genotypes) was **not** associated with significant changes in CBZ pharmacokinetics. Table 2 shows that none of the dose-adjusted concentrations or metabolite ratios differed significantly across CC, CT, and TT genotypes (all marked with the same letter \"a\"), and the paper explicitly states \"ABCB1 3455C>T SNP... were not associated with significant changes in CBZ pharmacokinetic.\"\n\nThe claim that genotype CC is not associated with metabolism of carbamazepine compared to CT + TT is therefore **supported**."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2298771 and carbamazepine in Disease:Epilepsy (PMCID PMC4640545), what p-value was reported for this association?", "answer": "> 0.05", "response": "Based on the paper, the SCN1A c.3184A>G (rs2298771) variant was **not associated** with significant changes in CBZ pharmacokinetics. Table 2 shows that all genotype groups (AA, AG, GG) share the same letter \"a\" for all parameters, indicating no statistically significant differences.\n\nNo specific p-value was reported for rs2298771's association with CBZ metabolism; the paper simply states that SCN1A c.3184A>G SNP \"does not affect CBZ metabolism\" and that differences were not significant (i.e., **p > 0.05**)."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "**false**"}]}
{"chain_id": "chain_000003", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4177494", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4177494, is the following pharmacogenomic claim supported or contradicted: Genotypes GG + GT is associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported.**\n\nThe paper shows that the rs8099917 TG/GG genotypes (carrying the G allele) were significantly associated with null-response (lack of HCV RNA decline \u22651 log at week 4) during PEG-IFN/RBV therapy, compared to the favorable TT genotype. Specifically, 81% of null-responders carried the rs8099917 G allele, and multivariate analysis confirmed rs8099917 G allele carriage as the best predictor of null-response (OR = 7.9). Additionally, among rs12979860 CT heterozygous patients, those with rs8099917 TG/GG had significantly less viral load reduction compared to those with TT. This demonstrates decreased response to peginterferon alfa-2a/2b plus ribavirin in GG/GT patients compared to TT."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs8099917 and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin in Disease:Hepatitis C virus infection (PMCID PMC4177494), what OR was reported?", "answer": "7.9", "response": "The study reported an **OR of 7.9** (95%CI: 1.99\u201331.18) for the rs8099917 G allele carriage as a predictor of null-response (HCV RNA decline <1 log10 IU/mL at week 4) during PEG-IFN/RBV therapy."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "**True.**\n\nThe 95% confidence interval (1.99\u201331.18) does not include 1.0, indicating statistical significance (P = 0.003)."}]}
{"chain_id": "chain_000004", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC7351433", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC7351433, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "Looking at the paper, I need to identify which SNP involves alleles G and T. The SLC19A1 rs1051266 polymorphism (G80A) has G and A alleles, not G and T. The MTHFR rs1801133 (C677T) has C and T alleles. The ABCB1 rs1045642 (C3435T) has C and T alleles.\n\nNone of the studied SNPs have both G and T as the relevant alleles. However, let me reconsider - the claim mentions \"allele G\" vs \"allele T.\" Looking at SLC19A1 rs1051266, the paper reports genotypes GG, GA, and AA. The paper found that SLC19A1 rs1051266 was **not** significantly associated with plasma MTX levels (it is not listed among the SNPs with significant associations with MTX plasma levels in Table 4 results). The significant associations with MTX plasma levels were for MTHFR rs1801133, ABCB1 rs1045642, and ABCG2 rs2231"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1801131 and methotrexate in Other:Acute lymphoblastic leukemia (PMCID PMC7351433), what p-value was reported for this association?", "answer": "> 0.05", "response": "The study reported a p-value of **P<0.05** for the association between MTHFR rs1801131 (AC genotype) and decreased hepatic toxicity related to methotrexate (OR: 0.313; 95% CI: 0.101-0.969)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "true"}]}
{"chain_id": "chain_000005", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3909071", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3909071, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported.**\n\nThe paper reports that for rs274618, the minor **T allele** was significantly associated with an increased risk of heroin dependence compared to the major **A allele** (not C). However, for rs274622, the comparison is between the minor **C allele** (risk allele) and the major **T allele** \u2014 which is the opposite direction of the claim.\n\nWait \u2014 let me re-read the claim carefully: \"Allele T is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele C.\"\n\nFor **rs274622**, the major allele is T and the minor allele is C. The **C allele** (not T) is the risk allele (OR = 1.652). So for rs274622, allele T compared to allele C would actually be the *protective* or reference allele.\n\nFor **rs274618**, the alleles are A (major) and T (minor), with T being the risk allele \u2014 but the comparison is T vs. A, not T vs. C.\n\nThe claim states \"Allele T is associated with increased risk..."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs13242038 and heroin in Other (PMCID PMC3909071)?", "answer": 619, "response": "**619** controls were included in the study."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "**true**"}]}
{"chain_id": "chain_000006", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5519037", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5519037, is the following pharmacogenomic claim supported or contradicted: Genotypes CT + TT are not associated with concentrations of everolimus in women with Breast Neoplasms as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Contradicted.**\n\nThe paper found that *CYP3A4* rs35599367 C>T variant carriers (C/T genotype) had significantly higher everolimus blood concentrations compared to wild-type (C/C) patients (median 69.1 ng/mL vs. 25.7 ng/mL, P = 0.019). This demonstrates a statistically significant association between the CT genotype and everolimus concentrations, contradicting the claim that CT + TT genotypes are not associated with everolimus concentrations."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs776746 and everolimus in Disease:Breast Neoplasms (PMCID PMC5519037), what p-value was reported for this association?", "answer": "> 0.05", "response": "The paper states that for *CYP3A5* rs776746 (*CYP3A5*3*) carriers (n = 4), **no statistically significant differences** were found in everolimus pharmacokinetics. No specific p-value was reported for this association."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "**false**"}]}
{"chain_id": "chain_000007", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5207665", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5207665, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with response to bevacizumab in women with Breast Neoplasms as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Contradicted.**\n\nThe paper identifies multiple SNPs where the A allele versus G allele is significantly associated with pathologic complete response (pCR) to bevacizumab. For example, ANGPT2 SNP rs2515462 (minor allele A vs. major allele G) showed a significant association with pCR (AOR 4.31, 95% CI 1.40\u201313.3, P = 0.011), and VEGFA SNPs rs833068 (minor allele A vs. major allele G) and rs833069 (minor allele G vs. major allele A) also showed significant associations with pCR. These findings contradict the claim that allele A is not associated with response to bevacizumab compared to allele G."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**\n\nThe study examines the statistical association between germline SNP genotypes and pathologic complete response (pCR) in breast cancer patients receiving bevacizumab plus chemotherapy. This is an observational/clinical study using logistic regression to identify associations between genetic variants and treatment outcomes, rather than a functional assay that would mechanistically characterize how specific alleles affect protein function, gene expression, or drug metabolism."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs17577 and bevacizumab in Disease:Breast Neoplasms (PMCID PMC5207665)?", "answer": 33, "response": "The SNP **rs17577 is not mentioned** in this paper (PMCID PMC5207665). The study examined 20 SNPs across six genes (ANGPT1, ANGPT2, FGF2, MMP9, TEK, and VEGFA) that were associated with pCR, but rs17577 was not among them. Therefore, the number of controls for rs17577 in relation to bevacizumab response cannot be determined from this study."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "**False**\n\nSince rs17577 is not mentioned in this paper, there are no controls (N = 0) for that specific SNP, which does not meet the minimum threshold of N \u2265 30."}]}
{"chain_id": "chain_000008", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC1689719", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC1689719, is the following pharmacogenomic claim supported or contradicted: G6PD deficiency is not associated with Hemolysis when treated with trimethoprim. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported**\n\nThe paper found that many commonly used drugs reported to accentuate haemolysis in G6PD deficiency did not actually shorten red-cell survival in their cross-transfusion studies. Trimethoprim (tested as co-trimoxazole, which contains trimethoprim and sulphamethoxazole) was among the drugs examined. The paper noted that sulphamethoxazole only aggravated haemolysis in some people, while trimethoprim itself was not identified as causing haemolysis. The finding that trimethoprim did not shorten red-cell survival in G6PD-deficient individuals supports the claim that G6PD deficiency is not associated with hemolysis when treated with trimethoprim."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**functional_assay**\n\nThe study used a **cross-transfusion technique** to measure red-cell survival in G6PD-deficient individuals exposed to various drugs. This is an experimental method where G6PD-deficient red cells were tracked (using radiolabeling, typically with \u2075\u00b9Cr) to directly measure the effect of drug exposure on red-cell lifespan. This constitutes a functional assay rather than a clinical association derived from observational or epidemiological data."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of G6PD deficiency and trimethoprim in Toxicity (PMCID PMC1689719)?", "answer": 8, "response": "Based on the paper, the study included **2** cases (subjects) in the investigation of G6PD deficiency and trimethoprim (tested as part of co-trimoxazole). The cross-transfusion technique was used on a small number of G6PD-deficient individuals for each drug tested, and trimethoprim (via co-trimoxazole) was tested in 2 subjects."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": false, "response": "**false**\n\nWith only 2 cases, the study does not meet the minimum threshold of N \u2265 30 for study cases."}]}
{"chain_id": "chain_000009", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC2850440", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC2850440, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with increased risk of Crohn Disease. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Contradicted.**\n\nThe paper shows that for SNP rs17234657, the minor allele G was significantly associated with increased risk of Crohn disease (OR = 1.8646, p = 0.0003 in European ancestry definite cases). Similarly, for SNP rs17221417, the minor allele G was also significantly associated with increased risk of Crohn disease (OR = 1.4562, p = 0.0086). These findings contradict the claim that allele G is not associated with increased risk of Crohn disease."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**\n\nThe study examines genotype-phenotype associations between SNP alleles and disease status (Crohn disease cases vs. controls) using odds ratios, chi-square tests, and logistic regression in a population derived from an EMR-linked DNA biorepository. This is a genetic association study, not a functional assay investigating biological mechanisms."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2542151 (PMCID PMC2850440), what OR was reported?", "answer": "1.0834", "response": "For rs2542151 in the Crohn disease analysis (European ancestry, definite cases), the reported allelic odds ratio was **1.0834** (95% CI: 0.74\u20131.58, p = 0.6774).\n\nThis association was not statistically significant."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "**False.**\n\nThe 95% confidence interval for rs2542151 was 0.74\u20131.58, which includes the null value of 1.0. This indicates the association was not statistically significant."}]}
{"chain_id": "chain_000010", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5331771", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5331771, is the following pharmacogenomic claim supported or contradicted: Genotypes AG + GG are associated with increased platelet reactivity when treated with aspirin and clopidogrel as compared to genotype AA. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported**\n\nThe paper examines CYP2C19*2 (rs4244285), where the wild-type allele is G>A. The CYP2C19*2 polymorphism (which involves the A allele as the variant/loss-of-function allele in standard nomenclature) was associated with higher PRU values (194.25 \u00b1 45.91 vs. 151.38 \u00b1 58.14, P < 0.001) in carriers compared to noncarriers.\n\nHowever, looking at this more carefully in the context of the specific claim about \"AG + GG vs. AA\": The rs4244285 SNP for CYP2C19*2 has G as the wild-type and A as the loss-of-function variant. The claim states that AG + GG (i.e., carrying at least one G/wild-type allele) is associated with *increased* platelet reactivity compared to AA. This doesn't align straightforwardly with the paper's findings, since CYP2C19*2 carriers (those with the A allele) had higher"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**\n\nThe study examines the relationship between genetic polymorphisms and platelet reactivity (measured by VerifyNow P2Y12 assay PRU values) as well as clinical outcomes (MACCE) in a cohort of 336 PCI-treated patients followed for 1 year. This represents observational clinical association data from a patient cohort, not a functional assay performed in a laboratory or in vitro setting."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2046934 and aspirin, clopidogrel in Efficacy (PMCID PMC5331771), what confidence interval was reported?", "answer": "1.64\u20133.53", "response": "The paper does not report a specific confidence interval for the association between rs2046934 (P2Y12) and efficacy outcomes in the context of aspirin and clopidogrel treatment. While the study does report P-values and odds ratios with 95% confidence intervals for some analyses (e.g., in the logistic regression tables), a specific confidence interval for the rs2046934 association with efficacy was **not explicitly reported** in the available text."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "Based on the information available in the paper, I **cannot determine** whether the confidence interval for the OR excludes 1.0. While the paper reports significant P-values for the P2Y12 (rs2046934) polymorphism association with endpoints (P = 0.001) and PRU levels (P = 0.008), the specific odds ratio and its confidence interval for rs2046934 are not explicitly provided in the text. The tables that would contain this information (particularly Table 6 on logistic regression) are referenced but their detailed numerical content is not fully reproduced in the available text.\n\nHowever, given that the reported P-values are statistically significant (P = 0.001 and P = 0.008), it is likely **true** that the confidence interval excludes 1.0, as statistical significance at P < 0.05 corresponds to a 95% CI that does not include the null value.\n\n**True**"}]}
{"chain_id": "chain_000011", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC6021962", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC6021962, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "Based on the paper, I need to identify which SNP has alleles T and C relevant to tacrolimus trough concentration.\n\nThe claim refers to a T vs C allele comparison. Looking at the CYP3A5*3 variant (rs776746), which involves a T/C change, this was **highly significantly** associated with tacrolimus trough concentrations in both the EA cohort (p = 6.08E-98) and the AA cohort (p = 2.34E-14).\n\nTherefore, the claim that allele T is **not** associated with trough concentration of tacrolimus compared to allele C is **contradicted** by this paper's findings.\n\n**Contradicted**"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs10264272 and tacrolimus in Disease:Kidney Transplantation, Disease:Transplantation (PMCID PMC6021962), what p-value was reported for this association?", "answer": "= 0.269", "response": "For rs10264272 (CYP3A5*6) in the African\u2013American cohort, the reported p-value was **0.269**. (In the European\u2013American cohort, it was not analyzed due to very low minor allele frequency [0.001].)"}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "**false**\n\nThe p-value of 0.269 is greater than 0.05, so the finding is not statistically significant."}]}
{"chain_id": "chain_000012", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4039076", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4039076, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with increased minimal residual disease when treated with asparaginase, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported**\n\nThe paper reports that the rs3824662 risk allele (allele A) in *GATA3* was associated with poorer early treatment response, including higher minimal residual disease (MRD). The COG protocols studied (AALL0232, P9905, P9906) used multi-agent chemotherapy regimens that include the drugs listed (asparaginase, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine, and vincristine) in children with B-precursor ALL (Precursor Cell Lymphoblastic Leukemia-Lymphoma). The rs3824662 A allele was associated with increased MRD and risk of relapse compared to the C allele, supporting this claim."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**\n\nThe evidence is based on a genome-wide association study (GWAS) examining the statistical association between the rs3824662 genotype and clinical outcomes (minimal residual disease, relapse risk) in children treated on COG clinical trials. This represents a clinical association derived from observational patient data rather than a functional assay performed in a laboratory setting."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3824662 and asparaginase, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine, vincristine in Disease:Acute lymphoblastic leukemia (PMCID PMC4039076), what p-value was reported for this association?", "answer": "= 0.039", "response": "The paper reports the association of rs3824662 with minimal residual disease (MRD) at end-of-induction. Based on the study findings, the p-value reported for the association of rs3824662 with MRD positivity (as a measure of early treatment response) was **P = 0.013**."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "**True**\n\nThe reported p-value of 0.013 is less than the significance threshold of \u03b1 = 0.05, making this finding statistically significant at that level."}]}
{"chain_id": "chain_000013", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC8602039", "num_turns": 2, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC8602039, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC8602039, rs74569896 is associated with Efficacy, Toxicity, Metabolism/PK outcomes for aspirin, clopidogrel. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "**Supported**\n\nThe paper reports that rs74569896 (in *NECAB1*) is significantly associated with major adverse cardiovascular events (MACE) in patients treated with clopidogrel and aspirin after PCI (meta P = 1.31 \u00d7 10\u207b\u2076; HR 1.90 in the replication cohort). MACE is a composite efficacy endpoint (cardiovascular death, myocardial infarction, stroke, and repeat revascularization), so the association with MACE represents an efficacy outcome for patients on aspirin and clopidogrel therapy. The claim that rs74569896 is associated with efficacy outcomes for aspirin and clopidogrel is therefore **supported**."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC8602039 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, the paper reports quantitative statistics for rs74569896 (*NECAB1*) and its association with MACE:\n\n**Discovery cohort (stage i):**\n- OR = 2.87 (95% CI: 1.51\u20135.45)\n- P = 3.87 \u00d7 10\u207b\u00b3\n\n**Replication cohort (stage ii):**\n- HR = 1.90 (95% CI: 1.39\u20132.61)\n- P = 5.91 \u00d7 10\u207b\u2075\n\n**Meta-analysis:**\n- P = 1.31 \u00d7 10\u207b\u2076\n\nThese values are reported in **Table 2** of the paper."}]}
{"chain_id": "chain_000014", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5538123", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5538123, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Contradicted.**\n\nThe paper found that rs6706232 in *UGT1A3* was significantly associated with risperidone response in the meta-analysis (P=0.024), with allele A accounting for a higher proportion in good responders compared with poor responders (25.2% vs 19.2% in the combined cohort). This indicates that allele A **is** associated with risperidone response compared to allele G, contradicting the claim that it is not associated."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs6313 and risperidone in Other:Schizophrenia (PMCID PMC5538123), what p-value was reported for this association?", "answer": "= 1", "response": "Based on the meta-analysis results in Table 4, the reported p-value for rs6313 and risperidone response was **P = 0.486** (allele-level association in the meta-analysis). The Bonferroni-corrected p-value was **1**."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "**False**\n\nThe p-value of 0.486 is far above the 0.01 significance threshold, so the association would not be significant at alpha = 0.01."}]}
{"chain_id": "chain_000015", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3773276", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3773276, is the following pharmacogenomic claim supported or contradicted: CYP2C19 *17 is not associated with post-treatment ADP-stimulated platelet aggregation when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported**\n\nThe paper shows that CYP2C19*17 was marginally associated with post-treatment ADP-stimulated platelet aggregation in single SNP analysis (P=0.01), but after adjusting for CYP2C19*2 (accounting for LD), the association was completely abolished (beta=\u22120.13, P=0.69). The stratified analyses further confirmed that among individuals who did not carry the *2 allele (i.e., *1/*1 vs. *1/*17 vs. *17/*17), there was no significant difference in ADP-stimulated platelet aggregation (P=0.96). The paper's main conclusion is that CYP2C19*17 is **not independently** associated with clopidogrel response, supporting the claim."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**functional_assay**\n\nThe PAPI Study measured ADP-stimulated platelet aggregation using optical aggregometry (a laboratory-based ex vivo functional assay) in healthy volunteers given clopidogrel under controlled conditions. This is a pharmacodynamic/functional measurement of drug response, not a clinical outcome (such as cardiovascular events, stent thrombosis, or bleeding). Therefore, this represents functional assay evidence."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of CYP2C19*17 and clopidogrel in Efficacy (PMCID PMC3773276), what p-value was reported for this association?", "answer": "= 0.01", "response": "The relevant p-value depends on the analysis:\n\n- **Single SNP analysis** (not adjusted for CYP2C19*2): **P = 0.01** for the association of CYP2C19*17 with post-treatment ADP-stimulated platelet aggregation.\n\n- **Multi-SNP analysis** (adjusted for CYP2C19*2): **P = 0.69**, showing no independent association.\n\nSince the paper's main conclusion is that CYP2C19*17 is not independently associated with clopidogrel response, the key reported p-value is **P = 0.69** from the multi-SNP analysis adjusting for CYP2C19*2."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "**False**\n\nThe key finding from the multi-SNP analysis (adjusted for CYP2C19*2) yielded P = 0.69, which is not statistically significant at alpha = 0.05. This supports the paper's conclusion that CYP2C19*17 has no independent association with clopidogrel response."}]}
{"chain_id": "chain_000016", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4864175", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4864175, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with risk of cognitive dysfunction due to opioids in people with Neoplasms as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported**\n\nThe paper found no confirmed associations between any of the SNPs analyzed and cognitive dysfunction in opioid-treated patients with cancer. While some initial associations were observed in the discovery sample, none were replicated in the validation sample, and after correction for multiple testing, no SNPs were significant. The paper's conclusion explicitly states: \"The findings did not support influence of those SNPs analyzed to explain cognitive dysfunction in opioid\u2010treated patients with cancer.\" This applies broadly to all alleles tested, including T vs. G allele comparisons across multiple SNPs (e.g., in genes like COMT rs5993882, IL6 rs2069835, HTR3E rs6443950, etc.). The claim of no association is consistent with the paper's negative findings."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**\n\nThe study is a cross-sectional multicenter clinical study (EPOS) examining associations between SNP genotypes and cognitive function (measured by MMSE scores) in 1586 opioid-treated cancer patients. This represents observational clinical association evidence, not a functional assay. No laboratory-based functional experiments were conducted to determine the mechanistic effects of any genetic variants."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs2160652 and opioids in Disease:Neoplasms (PMCID PMC4864175)?", "answer": 98, "response": "Based on the paper, the analysis of rs2160652 (in the TACR1 gene) in relation to cognitive dysfunction in opioid-treated cancer patients involved **1369 patients** in the overall MMSE analysis (after exclusions for missing data and quality control).\n\nFor the high opioid dose subgroup analysis (\u2265400 mg morphine equivalent dose/day), **300 patients** were analyzed, as indicated in Table 4.\n\nThe specific sample split was:\n- **Discovery sample**: 911 patients (overall) or 202 patients (high-dose subgroup)\n- **Validation sample**: 458 patients (overall) or 98 patients (high-dose subgroup)\n\nThe most appropriate answer depends on which analysis is being referenced. For the overall analysis, **1369 cases**; for the high-dose opioid subgroup (where rs2160652 showed a significant association in the dominant model in Table 4), **300 cases**."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "**True**\n\nWhether considering the overall analysis (1369 patients) or the high-dose opioid subgroup analysis (300 patients), both well exceed the minimum threshold of N \u2265 30."}]}
{"chain_id": "chain_000017", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4519434", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4519434, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported.**\n\nThe paper reports that the rs3778150-C allele (minor allele) is consistently associated with increased heroin addiction risk compared to the T allele across multiple cohorts and ancestry groups, with a meta-analysis P = 4.3\u00d710\u207b\u2078. The forest plot (Figure 2) and Table 1 show that the C allele confers odds ratios ranging from 1.15 to 1.28 for heroin addiction risk relative to the T allele."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**\n\nThe evidence represents a genetic association study testing SNP associations with heroin addiction in case-control cohorts (Urban Health Study, CIDR\u2013Gelernter Study, and Australian Heroin Dependence Study), rather than a functional assay measuring direct biological or molecular effects of the variant."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3778151 and heroin in Toxicity (PMCID PMC4519434), what p-value was reported for this association?", "answer": "= 3E-3", "response": "Based on the paper, rs3778151 was a previously implicated OPRM1 intron 1 SNP tested across the study cohorts. The meta-analysis P value reported for rs3778151's association with heroin addiction was **2.4\u00d710\u207b\u2077** (shown in Table 3)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "**True**\n\nThe meta-analysis P value for rs3778151 was 2.4\u00d710\u207b\u2077, which is far below the \u03b1 = 0.05 significance threshold."}]}
{"chain_id": "chain_000018", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5908896", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5908896, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with severity of Neutropenia when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported**\n\nThe claim refers to STAT-3 rs1053004 (T>C) and neutropenia. In the paper, STAT-3 rs1053004 was identified as a significant marker only for **gastrointestinal toxicity**, not for neutropenia. The polymorphism does not appear in Table 2 (which lists markers associated with grade 3\u20134 neutropenia at p < 0.05 in the discovery cohort), meaning it was not significantly associated with neutropenia. Therefore, the claim that the C allele is **not** associated with severity of neutropenia is supported by the paper's findings."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2972164 and fluorouracil, irinotecan, leucovorin in Disease:Colorectal Neoplasms (PMCID PMC5908896), what OR was reported?", "answer": "1.34", "response": "For **rs2972164** (PPARG) and its association with grade 3\u20134 **neutropenia** in the discovery cohort, the reported OR was **0.36** (95% CI: 0.16\u20130.82, p = 0.015) under a dominant model."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "**True**\n\nThe 95% confidence interval for the OR was **0.16\u20130.82**, which does not include 1.0, so the null value is excluded."}]}
{"chain_id": "chain_000019", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC2761685", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC2761685, is the following pharmacogenomic claim supported or contradicted: Genotype GG is associated with increased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported.**\n\nThe paper reports that homozygous G/G individuals at rs1051375 randomized to verapamil SR treatment had a greater than 4-fold increased risk of the primary outcome compared to G/G individuals randomized to atenolol treatment (OR 4.59, 95% CI 1.67\u201312.67). This directly supports the claim that the GG genotype is associated with increased risk of the primary outcome when treated with verapamil in patients with coronary artery disease."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**\n\nThe evidence comes from a nested case-control study within the INVEST-GENES clinical trial, examining the association between rs1051375 genotype and cardiovascular outcomes (death, nonfatal MI, nonfatal stroke) in patients randomized to different treatment strategies. This is a clinical association study, not a functional assay."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1051375 and verapamil in Disease:Coronary Artery Disease (PMCID PMC2761685), what confidence interval was reported?", "answer": "1.67\u201312.67", "response": "The confidence interval reported for the association between the rs1051375 G/G genotype and the primary outcome with verapamil treatment compared to atenolol treatment was **95% CI 1.67\u201312.67** (corresponding to an OR of 4.59)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "**True.**\n\nThe 95% confidence interval (1.67\u201312.67) does not include 1.0, indicating that the association is statistically significant."}]}
{"chain_id": "chain_000020", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC2966859", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC2966859, is the following pharmacogenomic claim supported or contradicted: Genotype CC is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported**\n\nThe paper examines *CDA* C111T (T145T) and finds no significant association between this SNP and tumor response to therapy. Looking at Table 4, the *CDA* C111T variant is not listed among the SNPs significantly associated with tumor response \u2014 only *CDA* A-76C and *hENT1* A-201G were significant. Furthermore, in Table 5 (PFS analysis), *CDA* C111T CC vs. CT/TT showed no significant association with progression-free survival (P = .473 for log-rank, HR = 1.22, P = .281). Thus, the claim that genotype CC (of *CDA* C111T) is not associated with increased response to gemcitabine compared to CT/TT is supported by the paper's findings."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs9394992 and gemcitabine in Disease:Pancreatic Neoplasms (PMCID PMC2966859), what HR was reported?", "answer": "1.08", "response": "Based on Table 5 in the paper, for *hENT1* C913T (rs9394992), the reported HR was **1.08** (95% CI: 0.74\u20131.57, P = .704) for the comparison of CC/TT vs. CT genotypes in relation to progression-free survival."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the HR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "**False**\n\nThe 95% confidence interval for the HR was 0.74\u20131.57, which includes the null value of 1.0."}]}
{"chain_id": "chain_000021", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3619396", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3619396, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with risk of Hypersensitivity when treated with sulfamethoxazole / trimethoprim in people with Infection. Answer one of: supported, contradicted.", "answer": "supported", "response": "Based on the paper, I need to determine which SNP has allele T as the minor allele and whether it's associated with sulfonamide hypersensitivity.\n\nLooking at the NAT2 SNPs in Table 3, several have T as the minor allele:\n\n- **282 C>T**: Minor allele frequencies were 0.288 (HS) vs. 0.323 (TOL), P = 0.70 \u2014 not significant\n- **481 C>T**: Minor allele frequencies were 0.455 (HS) vs. 0.399 (TOL), P = 0.41 \u2014 not significant\n- **341 T>C**: Here T is the reference allele, not the minor allele\n\nThe paper's overall conclusion is that NAT2 allele and haplotype frequencies did not differ between hypersensitive and tolerant patients, and no significant associations were found for any of the tested variants.\n\nThe claim that \"Allele T is not associated with risk of Hypersensitivity when treated with sulfamethoxazole/trimethoprim in people with Infection"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs77005399 and sulfamethoxazole / trimethoprim in Disease:Infectious disease (PMCID PMC3619396)?", "answer": 99, "response": "Based on Table 2, the study included **99** hypersensitive (HS) cases for the analysis of rs77005399 (CYB5A \u2212389G>A) and sulfamethoxazole/trimethoprim."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "**true**"}]}
{"chain_id": "chain_000022", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3798385", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3798385, is the following pharmacogenomic claim supported or contradicted: Genotype CG is associated with increased risk of Neurotoxicity Syndromes when treated with carboplatin, docetaxel and paclitaxel in women with Ovarian Neoplasms as compared to genotypes CC + GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported.**\n\nFrom Table 2, the SNP rs139887 in *SOX10* shows that the CG (heterozygous) genotype is the risk genotype for neurotoxicity. The proportion of cases per genotype shows CG = 98/355 = 0.28, which is higher than both CC = 24/111 = 0.22 and GG = 58/320 = 0.18. This indicates that the heterozygous CG genotype carries increased risk of neurotoxicity compared to the homozygous genotypes (CC and GG), consistent with an overdominant/heterozygous risk model. The study was conducted in ovarian cancer patients treated with carboplatin combined with either docetaxel or paclitaxel."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs139887 and carboplatin, docetaxel, paclitaxel in Disease:Ovarian Neoplasms (PMCID PMC3798385), what OR was reported?", "answer": "1.77", "response": "The reported odds ratio (OR) for rs139887 (SOX10) was **1.77** (95% CI: 1.21\u20132.59)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "**True.**\n\nThe 95% confidence interval for the OR is (1.21, 2.59), which does not include 1.0, indicating a statistically significant association."}]}
{"chain_id": "chain_000023", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC9031832", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC9031832, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity and Fetal Alcohol Syndrome as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported.**\n\nThe paper found no effect of the COMT rs4680 A allele (Met158) on MPH treatment efficacy. As stated in the results: \"No effect of COMT (rs4680) and DRD2 (rs1076560, rs1800497) polymorphisms and the treatment efficacy was observed.\" The A allele was associated with adverse effects (p = 0.04994) but not with treatment response. The authors concluded that \"the analyzed DRD2 and COMT gene polymorphisms seem to play no role in MPH efficacy in ADHD children with hPAE.\" Thus, the claim that allele A is **not** associated with increased response to methylphenidate is supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs1800497 and methylphenidate in Other:Attention Deficit Disorder with Hyperactivity, Other:Fetal Alcohol Syndrome (PMCID PMC9031832)?", "answer": 114, "response": "Based on the paper, **114** cases (children with ADHD who were treated with methylphenidate) were included in the study analyzing rs1800497 and methylphenidate response. This is shown in Table 7, where n = 114 for the MPH treatment group."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "**true**"}]}
{"chain_id": "chain_000024", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC9957000", "num_turns": 2, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC9957000, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC9957000, rs4149056 is associated with PD, Metabolism/PK outcomes for atorvastatin, simvastatin. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "**Contradicted**\n\nThe paper specifically investigated whether rs4149056 (SLCO1B1 c.521T>C) is associated with changes in statin therapy (dose changes, discontinuation/switching, and time to stable dosing) for both atorvastatin and simvastatin. The authors found **no statistically significant association** between the SLCO1B1 c.521T>C genotype and any of these outcomes for either statin. The claim states that rs4149056 **is** associated with PD/Metabolism/PK outcomes for these statins, which is directly contradicted by the paper's findings."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC9957000 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "**Yes.** The paper reports quantitative statistics for the association between rs4149056 and outcomes for both atorvastatin and simvastatin. From Table 2:\n\n**Simvastatin:**\n- Dose change: Crude OR = 0.50 (95% CI 0.19\u20131.31); Adjusted OR = 0.42 (95% CI 0.15\u20131.16)\n- Any change (discontinuation/switch): Crude OR = 0.93 (95% CI 0.69\u20131.25); Adjusted OR = 0.80 (95% CI 0.58\u20131.11)\n- Time to stable dosing: Crude HR = 1.02 (95% CI 0.87\u20131.21); Adjusted HR = 1.06 (95% CI 0.89\u20131.26)\n\n**Atorvastatin:**\n- Dose change: Crude OR = 1.72 (95% CI 0.42\u20137.11); Adjusted OR = 1.97 (95% CI 0."}]}
{"chain_id": "chain_000025", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4519434", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4519434, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with increased risk of Heroin Dependence due to heroin as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "Based on the paper, the claim that the rs1799971-A allele is associated with increased risk of heroin dependence compared to the G allele is **supported**.\n\nThe paper states that the direction of association for rs1799971 \"generally suggested that the major allele (A) conferred an increased risk with heroin addiction.\" Furthermore, the haplotype analysis showed that the rs1799971-A allele was significantly associated with increased heroin addiction risk when on the same haplotype as rs3778150-C (meta-analysis P=1.5\u00d710\u207b\u2076), with the haplotype carrying both rs3778150-C and rs1799971-A consistently associated with increased risk across all cohorts. The paper's findings support that the A allele (rather than G) confers increased risk, though the association is dependent on haplotype context (specifically the presence of rs3778150-C)."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**\n\nThe study examines the association between genetic variants (SNPs) and heroin addiction risk across multiple case-control cohorts (Urban Health Study, CIDR\u2013Gelernter Study, and Australian Heroin Dependence Study), using logistic regression and meta-analysis to test for statistical associations between genotypes/haplotypes and disease status. This is a genetic association study, not a functional assay measuring direct biological/molecular effects of the variants."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3823010 and heroin in Toxicity (PMCID PMC4519434), what confidence interval was reported?", "answer": "1.1\u20131.37", "response": "Based on the paper, for rs3823010, confidence intervals were reported for each individual cohort but not a single overall meta-analysis confidence interval. The cohort-specific confidence intervals reported in Table 3 were:\n\n- **Urban Health Study, African Americans:** OR 1.19 **(95% CI: 1.02-1.37)**\n- **Urban Health Study, European Americans:** OR 1.28 **(95% CI: 1.11-1.49)**\n- **CIDR \u2013 Gelernter Study, African Americans:** OR 1.25 **(95% CI: 0.91-1.72)**\n- **Australian Heroin Dependence Study:** OR 1.23 **(95% CI: 1.10-1.37)**\n\nNo single combined confidence interval was provided for the overall meta-analysis result of rs3823010 (meta-analysis P=2.7\u00d710\u207b\u2078)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "**True**\n\nLooking at the individual cohort results for rs3823010, the majority of the confidence intervals exclude 1.0:\n\n- UHS African Americans: 95% CI 1.02-1.37 (excludes 1.0)\n- UHS European Americans: 95% CI 1.11-1.49 (excludes 1.0)\n- Australian Heroin Dependence Study: 95% CI 1.10-1.37 (excludes 1.0)\n\nOnly the CIDR\u2013Gelernter Study African Americans (95% CI 0.91-1.72) includes 1.0, which was the smallest cohort with less statistical power. The overall meta-analysis P value of 2.7\u00d710\u207b\u2078 strongly indicates that the combined result excludes the null value of 1.0."}]}
{"chain_id": "chain_000026", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4752391", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4752391, is the following pharmacogenomic claim supported or contradicted: Genotype TTA/del is associated with increased response to atenolol, hydrochlorothiazide or metoprolol in people with Hypertension as compared to genotype TTA/TTA. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported**\n\nThe paper shows that the SLC25A31 rs201279313 deletion variant (TTA deletion) is associated with greater blood pressure reduction in response to \u03b2-blockers. Specifically, African American participants heterozygous for the deletion (TTA/del) had better diastolic blood pressure response compared to wild-type (TTA/TTA) across all three treatment groups: atenolol monotherapy (\u22129.3 vs. \u22124.6 mmHg), metoprolol monotherapy (\u22129.6 vs. \u22124.8 mmHg), and atenolol add-on to hydrochlorothiazide therapy (\u22129.7 vs. \u22126.4 mmHg). The claim that TTA/del is associated with increased response to atenolol, hydrochlorothiazide, or metoprolol is supported by these findings (noting the hydrochlorothiazide component was part of the add-on therapy context)."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**\n\nThe study is a pharmacogenomic genome-wide meta-analysis examining the statistical association between genetic variants and blood pressure response to \u03b2-blockers in clinical trial participants. It involves observational analysis of genotype-phenotype relationships in hypertensive patients treated in clinical settings (PEAR-1 and PEAR-2 studies), not any laboratory-based functional experiments to determine biological mechanism."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs201279313 and atenolol, hydrochlorothiazide, metoprolol in Disease:Hypertension (PMCID PMC4752391), what p-value was reported for this association?", "answer": "= 1.10E-07", "response": "The study reports multiple p-values for rs201279313 across the different treatment groups:\n\n- **Atenolol monotherapy:** p = 5.8\u00d710\u207b\u2074\n- **Metoprolol monotherapy:** p = 5.3\u00d710\u207b\u2075\n- **Atenolol add-on to hydrochlorothiazide:** p = 0.033\n- **3-group meta-analysis:** p = **2.5\u00d710\u207b\u2078**\n\nThe primary reported p-value for the overall association is **2.5\u00d710\u207b\u2078** from the 3-group meta-analysis, with a beta of \u22124.42 mmHg per deletion allele."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "**true**\n\nThe 3-group meta-analysis p-value of 2.5\u00d710\u207b\u2078 is far below the 0.05 significance threshold, and indeed also surpasses the genome-wide significance threshold of 5\u00d710\u207b\u2078."}]}
{"chain_id": "chain_000027", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC12032684", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC12032684, is the following pharmacogenomic claim supported or contradicted: Genotypes CC + CT is associated with increased likelihood of statin-related myopathy when treated with atorvastatin in people with Cardiovascular Disease, Diabetes Mellitus, Acute coronary syndrome or Dyslipidaemia as compared to genotype TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported**\n\nThe paper reports that atorvastatin users carrying the C allele at *SLCO1B1* rs4149056 (521T>C) \u2014 i.e., CT or CC genotypes \u2014 had a significantly increased risk of statin-associated muscle symptoms (SAMS) compared to non-carriers (TT). Specifically, Table 4 shows an OR of 2.202 (95% CI 1.287\u20133.811, P = 0.0063) in the univariate analysis, and the logistic regression in Table 6 confirmed this with an adjusted OR of 2.047 (95% CI 1.162\u20133.608, P = 0.013). The cohort included patients with cardiovascular disease, diabetes mellitus, acute coronary syndrome, and dyslipidemia. This supports the claim that CC + CT genotypes are associated with increased likelihood of statin-related myopathy with atorvastatin compared to TT."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs4149056 and atorvastatin in Other:Cardiovascular Disease, Other:Diabetes Mellitus, Other:Acute coronary syndrome, Other:Dyslipidaemia (PMCID PMC12032684), what OR was reported?", "answer": "2.202", "response": "The study reported an **adjusted OR of 2.047** (95% CI 1.162\u20133.608, P = 0.013) from the logistic regression analysis (Table 6) for the association between *SLCO1B1* rs4149056 C allele carriers and SAMS among atorvastatin users."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "**True**\n\nThe 95% confidence interval (1.162\u20133.608) does not include 1.0, indicating a statistically significant association."}]}
{"chain_id": "chain_000028", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC11050844", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11050844, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased likelihood of primary graft failure or Kidney Tubular Necrosis, Acute when treated with mycophenolic acid and tacrolimus in people with Kidney Transplantation as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported**\n\nThe paper found that the wildtype ABCC2 -24C>T **C allele** was associated with a higher risk of developing acute graft rejection and/or ATN compared to the variant **T allele** carriers (aOR: 27.675, p = 0.038) in kidney transplant recipients treated with tacrolimus and mycophenolic acid. This directly supports the claim that allele C is associated with increased likelihood of primary graft failure or acute kidney tubular necrosis compared to allele T in this treatment and population context."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**\n\nThe study is a retrospective cohort study examining the statistical association between ABCC2 -24C>T genotypes and clinical outcomes (acute graft rejection and/or ATN) in kidney transplant recipients using logistic regression analysis. It does not involve any in vitro or in vivo functional assays measuring transporter activity, gene expression, or protein function. This is purely an observational clinical association study."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs717620 and mycophenolic acid, tacrolimus in Other:Kidney Transplantation (PMCID PMC11050844), what p-value was reported for this association?", "answer": "= 0.038", "response": "The p-value reported for the association between the ABCC2 -24C>T (rs717620) C allele and acute graft rejection and/or ATN in kidney transplant recipients treated with mycophenolic acid and tacrolimus was **p = 0.038** in the multiple logistic regression model."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "**true**\n\nThe reported p-value of 0.038 is less than the significance threshold of alpha = 0.05, making this finding statistically significant. The authors also used p < 0.05 as their threshold for statistical significance in the study."}]}
{"chain_id": "chain_000029", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC8673616", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC8673616, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported**\n\nIn Table 3, the association between OPRM1 rs1799971 (minor allele G vs. major allele A) and methadone dose was not significant (\u03b2 = 0.20, SE = 2.90, P = 0.95) in the total sample. The sex-stratified analyses were also non-significant (males: \u03b2 = 2.59, P = 0.49; females: \u03b2 = -4.92, P = 0.29). Therefore, the claim that allele G is not associated with methadone dose compared to allele A is supported by the paper's findings."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs10485058 and methadone in Other:Opioid-Related Disorders (PMCID PMC8673616)?", "answer": 1165, "response": "Based on Table 3, the analysis of rs10485058 and methadone dose included **1,165** participants."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "**true**"}]}
{"chain_id": "chain_000030", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC8291172", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC8291172, is the following pharmacogenomic claim supported or contradicted: Allele G is associated with decreased likelihood of Hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported.**\n\nThe paper reports that for rs2790, carriers of the G allele had a **lower risk** of developing grade 2\u20133 HFS (OR, 0.58; 95% CI, 0.39 to 0.87; p=8.80\u00d710\u207b\u00b3). This means the G allele of rs2790 is associated with a decreased likelihood of capecitabine-induced hand-foot syndrome compared to the A allele in colorectal cancer patients."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3786362 and capecitabine in Other:Colorectal Neoplasms (PMCID PMC8291172), what OR was reported?", "answer": "0.38", "response": "The reported OR for rs3786362 was **0.38** (95% CI, 0.21 to 0.70; p=1.89\u00d710\u207b\u00b3)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "**True**\n\nThe 95% confidence interval for rs3786362 was 0.21 to 0.70, which does not include 1.0, indicating a statistically significant association."}]}
{"chain_id": "chain_000031", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5721751", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5721751, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with decreased response to atenolol and hydrochlorothiazide in people with Hypertension as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported**\n\nThe paper reports that the rs261316 major allele **T** is associated with an increased odds of having **uncontrolled** BP on thiazide diuretic/\u03b2-blocker combination therapy (i.e., decreased response). The minor allele **C** would then be associated with **better** BP control (i.e., better response). The claim states that allele C is associated with **decreased** response compared to allele T \u2014 this is the opposite: allele T is the one associated with decreased response (uncontrolled BP), not allele C.\n\nWait \u2014 let me re-read the claim carefully: \"Allele C is associated with decreased response to atenolol and hydrochlorothiazide... as compared to allele T.\"\n\nThe paper shows allele T (major allele) is associated with **increased odds of uncontrolled BP** (OR: 2.56), meaning T carriers have worse/decreased response. Allele C (minor allele) would be associated with **better** response. The claim says C has decreased response compared to T, which is the reverse of what the paper found.\n\n**"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs35123024 and atenolol, hydrochlorothiazide in Disease:Hypertension (PMCID PMC5721751), what OR was reported?", "answer": "3.71", "response": "The study reported an OR of **3.71** for rs35123024 in the PEAR discovery cohort (95% confidence interval: 2.13\u20136.45, P=3.46E\u201006), where the minor allele (C) was associated with increased odds of having uncontrolled BP on atenolol and hydrochlorothiazide combination therapy."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "**True**\n\nThe 95% confidence interval for rs35123024 in the PEAR discovery cohort was **2.13\u20136.45**, which does not include 1.0, indicating a statistically significant association."}]}
{"chain_id": "chain_000032", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC5558540", "num_turns": 2, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5558540, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC5558540, rs4141964 is associated with Toxicity outcomes for morphine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "**Supported**\n\nThe paper reports that rs4141964 was significantly associated with morphine-induced depression of hypercapnic ventilatory response (HCVR) (p < 0.0001), which is a measure of morphine-related respiratory depression \u2014 a toxicity/adverse outcome. HCVR was shown to predict clinical respiratory depression (RD), a serious morphine toxicity. Additionally, the paper's previous study (referenced as ref 17) found rs4141964 associated with postoperative nausea and vomiting (PONV), another morphine toxicity outcome. Thus, rs4141964 is associated with toxicity outcomes for morphine."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC5558540 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "**Yes.** The paper reports quantitative statistics for rs4141964 in Table 3:\n\n- **HCVR (ventilatory response):** \u03b2 = -0.633, **p < 0.0001**\n- **Postoperative vomiting:** OR = 0.70, 95% CI: 0.41\u20131.18, p = 0.1767\n- **Clinical respiratory depression:** OR = 0.71, 95% CI: 0.4\u20131.27, p = 0.2519\n\nThe highly significant association (p < 0.0001) is with morphine-induced depression of hypercapnic ventilatory response, which the authors establish as an objective indicator of impending/subclinical respiratory depression \u2014 a morphine toxicity outcome."}]}
{"chain_id": "chain_000033", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC10193607", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC10193607, is the following pharmacogenomic claim supported or contradicted: Allele G is associated with increased likelihood of transplant rejection when treated with tacrolimus in children with Kidney Transplantation as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Contradicted**\n\nThe paper studied the MDR1 G2677T polymorphism and found that the **T allele** (not the G allele) was associated with increased risk of acute rejection in pediatric kidney transplant recipients treated with tacrolimus. Specifically, the GT and TT genotypes and the T allele were significantly higher among the acute rejection group compared to the non-rejection group (P = 0.023, 0.033, and 0.028 respectively). The GG genotype was associated with the best survival in the Kaplan-Meier analysis. Therefore, the claim that the G allele is associated with increased rejection risk is contradicted by the study's findings."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**\n\nThe study is a cross-sectional, case-control study that examines the association between MDR1 gene polymorphisms (C3435T and G2677T) and clinical outcomes (acute rejection, tacrolimus pharmacokinetics) in pediatric kidney transplant recipients. It uses genotyping and statistical comparisons of clinical outcomes between genotype groups, rather than any in vitro or in vivo functional assays measuring P-glycoprotein activity or expression directly."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1045642 and tacrolimus in Other:Kidney Transplantation (PMCID PMC10193607), what p-value was reported for this association?", "answer": "= 0.01", "response": "The study reported multiple p-values for the association between rs1045642 (C3435T) and acute rejection in kidney transplant recipients treated with tacrolimus. Comparing the AR group versus the None AR group:\n\n- **CC genotype**: P = **0.008**\n- **CT genotype**: P = **0.001**\n- **C allele**: P = **0.01**\n\nThese were the primary association results for rs1045642 (C3435T) with acute rejection risk. The most significant p-value reported for this SNP's association with acute rejection was **p = 0.001** (for the CT genotype comparison between AR and None AR groups)."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "**True**\n\nThe CT genotype association had a p-value of 0.001 and the CC genotype had a p-value of 0.008, both of which are below the alpha = 0.01 threshold. The C allele association had a p-value of 0.01, which is right at the threshold and would also be considered significant at alpha = 0.01."}]}
{"chain_id": "chain_000034", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC3164878", "num_turns": 2, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3164878, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC3164878, rs671531 is associated with Toxicity outcomes for fentanyl. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "**not_reported**\n\nThe paper examines rs671531 (SNP13) in the context of association with alcohol dependence (AD) and drug dependence (DD), not in relation to toxicity outcomes for fentanyl. The study focuses on substance dependence phenotypes, and rs671531 is mentioned as one of the 13 OPRM1 SNPs studied, but no association with fentanyl toxicity is discussed anywhere in the paper."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC3164878 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "**no**\n\nThe paper does not report any quantitative statistics (p-value, OR, or CI) related to fentanyl toxicity outcomes for rs671531 or any other SNP. Fentanyl is not mentioned in the paper, and toxicity outcomes are not assessed. The study exclusively examines associations between OPRM1 variants and substance dependence phenotypes (alcohol dependence and drug dependence)."}]}
{"chain_id": "chain_000035", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3749570", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3749570, is the following pharmacogenomic claim supported or contradicted: Genotype CC is not associated with response to cyclophosphamide in people with Prostatic Neoplasms as compared to genotypes CG + GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Contradicted.**\n\nThe paper shows that the VEGF-A \u2212634CC genotype was significantly associated with worse response to metronomic cyclophosphamide in prostate cancer patients. Specifically, the \u2212634CC genotype frequency was 22.73% in non-responders vs 0% in responders (P=0.0485), and patients with the \u2212634CC genotype had a significantly shorter median PFS (2.2 months) compared to patients with \u2212634CG/GG genotypes (6.25 months, P=0.0042). Therefore, the claim that CC is **not** associated with response is contradicted by these findings."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2010963 and cyclophosphamide in Disease:Prostatic Neoplasms (PMCID PMC3749570), what p-value was reported for this association?", "answer": "= 0.0485", "response": "The study reported a p-value of **0.0042** for the association between the VEGF-A \u2212634C/G (rs2010963) genotype and progression-free survival (PFS) in prostate cancer patients treated with metronomic cyclophosphamide (\u2212634CC: median PFS 2.2 months vs \u2212634CG/GG: median PFS 6.25 months).\n\nAdditionally, a p-value of **0.0485** was reported for the association between the \u2212634CC genotype and PSA response (responders vs non-responders)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "**True**\n\nThe key finding (PFS association, P=0.0042) is statistically significant even after Bonferroni correction (threshold P<0.017). The PSA response association (P=0.0485) is also below the conventional alpha of 0.05, though it did not survive Bonferroni correction."}]}
{"chain_id": "chain_000036", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC4660479", "num_turns": 2, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4660479, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC4660479, rs4149087 is associated with Toxicity outcomes for enalapril. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "**not_reported**\n\nThe paper (PMC4660479) investigates two SLCO1B1 variants: rs2306283 (388A>G) and rs4149056 (521T>C). The SNP rs4149087 is not mentioned anywhere in the study. Therefore, any claim about rs4149087 and its association with enalapril-related outcomes is not reported in this paper."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC4660479 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "**No**, PMC4660479 does not report any quantitative statistic (p-value, OR, or CI) for rs4149087, as this SNP is not mentioned or analyzed anywhere in the paper."}]}
{"chain_id": "chain_000037", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC8426351", "num_turns": 2, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC8426351, is the following pharmacogenomic claim supported, contradicted, or not reported: Genotypes CT + TT is associated with decreased concentrations of rivaroxaban in men as compared to genotype CC. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC8426351 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMCID PMC8426351 does not report any quantitative statistic (p-value, OR, or CI) for this claim. The paper does not study rivaroxaban at all; it focuses on the pharmacokinetics of teneligliptin in relation to FMO3 and CYP3A4 polymorphisms."}]}
{"chain_id": "chain_000038", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5488790", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5488790, is the following pharmacogenomic claim supported or contradicted: UGT1A1 *6 + *28 is not associated with increased likelihood of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms or Lung Neoplasms as compared to UGT1A1 *1/*1. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported**\n\nThe paper found no significant association between UGT1A1*6/*28 mutant genotypes and severe neutropenia in either colorectal cancer or lung cancer patients. Specifically:\n\n- In colorectal cancer patients, when UGT1A1*6 and *28 mutant genotypes were considered together (mutant type), the incidence of severe (grade III\u2013IV) neutropenia was 25.00% in wild-type vs 25.00% in mutant type (P=1.000) (Table 5).\n- In lung cancer patients, severe neutropenia showed no significant difference between wild-type and mutant genotypes (P=0.700) (Table 5).\n- Overall, the authors state: \"neither UGT1A1*6 nor UGT1A1*28 mutations were associated with severe neutropenia.\"\n\nThis supports the claim that UGT1A1 *6+*28 is not associated with increased likelihood of neutropenia compared to wild-type in these tumor types."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of UGT1A1*1, UGT1A1*6, UGT1A1*28 and irinotecan in Other:Colorectal Neoplasms, Other:Lung Neoplasms (PMCID PMC5488790), what p-value was reported for this association?", "answer": "= 0.7", "response": "The paper reports multiple p-values for the association between UGT1A1*6/*28 combined mutant genotypes and neutropenia in these tumor types:\n\n- **Colorectal cancer**: P = **1.000** (for severe neutropenia, mutant type vs wild-type, Table 5)\n- **Lung cancer**: P = **0.700** (for severe neutropenia, mutant type vs wild-type, Table 5)\n\nNeither reached statistical significance, consistent with no association."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "**false**"}]}
{"chain_id": "chain_000039", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC3232196", "num_turns": 2, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3232196, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC3232196, rs1045642 is associated with Toxicity, Metabolism/PK outcomes for buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine, tramadol. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC3232196 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMCID PMC3232196 does not report any quantitative statistic (p-value, OR, or CI) for an association between rs1045642 and toxicity or metabolism/PK outcomes for any of those opioid drugs (buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine, tramadol). The study examines rs1045642 (ABCB1 3435C>T) only in the context of efavirenz-based antiretroviral and rifampicin-based anti-TB drug-induced liver injury."}]}
{"chain_id": "chain_000040", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC2072824", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC2072824, is the following pharmacogenomic claim supported or contradicted: HLA-B *44:02 + *44:03 is associated with increased risk of Drug Hypersensitivity when exposed to trichloroethylene. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "**Supported**\n\nThe paper found that HLA-B*44 alleles (including B*4402 and B*4403) were present in 6.2% (7/113) of TCE-induced hypersensitivity dermatitis cases but were completely absent in the 142 TCE-tolerant controls (OR = 20.1; 95% CI, 2.6\u2013157.5; p = 0.003). Although the corrected p-value was > 0.05 (meaning it did not reach statistical significance after Bonferroni correction), the authors noted this as a potentially real association rather than a chance finding, and the direction of the association is consistent with increased risk of hypersensitivity when exposed to trichloroethylene."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**\n\nThe study is a population-based case\u2013control study comparing HLA allele frequencies between TCE-induced hypersensitivity dermatitis patients and TCE-tolerant controls. This represents an observational clinical association between genetic variants and disease outcome, not a functional assay."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of HLA-B*44:02, HLA-B*44:03 and trichloroethylene in Toxicity (PMCID PMC2072824)?", "answer": 113, "response": "**113 cases** were included in the study with complete genotyping data. Of these 113 cases with TCE-induced hypersensitivity dermatitis, 7 (6.2%) carried the HLA-B*44 alleles (B*4402 and B*4403)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "**True**\n\nThe study included 113 cases with complete genotyping data, which exceeds the minimum threshold of N \u2265 30 for study cases."}]}
{"chain_id": "chain_000041", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC7156285", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC7156285, is the following pharmacogenomic claim supported or contradicted: HLA-A *31:01 is associated with increased risk of drug-induced liver injury when treated with carbamazepine. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported**\n\nThe paper reports that 33% of CBZ-DILI cases were HLA-A*31:01 carriers, with an OR of 7.3 (95% CI 2.47\u201323.67; P = 0.0004), indicating a significant association between HLA-A*31:01 and increased risk of carbamazepine-induced liver injury."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of HLA-A*31:01 and carbamazepine in Toxicity (PMCID PMC7156285), what confidence interval was reported?", "answer": "2.47\u201323.67", "response": "The confidence interval reported for the association of HLA-A*31:01 with CBZ-DILI was **95% CI 2.47\u201323.67** (OR = 7.3)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "**True**\n\nThe confidence interval (2.47\u201323.67) does not include 1.0, indicating a statistically significant association."}]}
{"chain_id": "chain_000042", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC12098310", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC12098310, is the following pharmacogenomic claim supported or contradicted: Genotypes CT + TT is associated with decreased likelihood of Progression-free survival and overall survival when treated with doxorubicin in people with Hepatocellular Carcinoma as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported.**\n\nThe paper found that for CBR1 rs3787728, T allele carriers (TC and TT genotypes) had significantly shorter median OS and median PFS compared to the homozygous CC genotype. Specifically, the heterozygous TC genotype was associated with a reduced median OS (13.7 months vs. 19.3 months for CC) with HR 5.3 (CI 1.07\u201326.3, p=0.04), and when TC+TT were pooled together versus CC, the log rank p=0.045 for OS. Similarly, TC genotypes demonstrated a markedly reduced median PFS of 7.1 months compared to 59.4 months for CC homozygotes. This confirms that CT+TT genotypes are associated with decreased likelihood of PFS and OS compared to CC."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3787728 and doxorubicin in Other:Hepatocellular Carcinoma (PMCID PMC12098310), what p-value was reported for this association?", "answer": "= 0.045", "response": "The study reported multiple p-values for the association between rs3787728 and outcomes in doxorubicin-treated HCC patients:\n\n- **Overall survival (OS):** KM log-rank **p = 0.046** for the three-genotype comparison; HR for TC vs CC genotype **p = 0.04**; pooled T allele carriers (TC+TT) vs CC **p = 0.045**\n- **Progression-free survival (PFS):** KM log-rank **p = 0.054** for the three-genotype comparison; HR for TC vs CC **p = 0.077**\n\nThe most significant individual p-value reported for this association was **p = 0.04** (Cox proportional hazard analysis for the TC heterozygous genotype vs. CC homozygous genotype and OS)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "**True**"}]}
{"chain_id": "chain_000043", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC11062152", "num_turns": 2, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11062152, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC11062152, UGT1A1*1, UGT1A1*6, UGT1A1*28 is associated with Dosage, Efficacy outcomes for fluorouracil, irinotecan, leucovorin. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "**Supported**\n\nThe paper reports that UGT1A1*6 and *28 polymorphism status (wild-type, heterozygous, homozygous) is associated with dosage of nanoliposomal irinotecan (nal-IRI) in the nal-IRI/FL regimen. Specifically, patients with UGT1A1*6 or *28 (+/+) received significantly lower initial nal-IRI doses (48 mg/m\u00b2 median) compared to wild-type patients (56 mg/m\u00b2) (p=0.011), consistent with dose-reduction recommendations. The wild-type allele (*1) is implicitly referenced as the baseline. While the study focuses primarily on adverse events (toxicity) rather than efficacy outcomes per se, the dosage association with UGT1A1 genotype is clearly supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC11062152 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, the paper reports quantitative statistics relevant to this claim:\n\n1. **Dosage association with UGT1A1 genotype:**\n   - Initial nal-IRI doses differed significantly among UGT1A1*6 or *28 genotype groups (**p=0.011**)\n   - Median doses: (\u2013/\u2013) 56 mg/m\u00b2, (+/\u2013) 56 mg/m\u00b2, (+/+) 48 mg/m\u00b2\n\n2. **Adverse event associations (toxicity/safety outcomes):**\n   - White blood cell nadir: UGT1A1*6 or *28 (+/+) significantly lower (**p=0.033**); multiple regression **p=0.009**\n   - Neutrophil nadir: UGT1A1*6 or *28 (+/+) significantly lower (**p=0.043**); multiple regression **p=0.017**\n   - Grade \u22653 leukopenia/neutropenia incidence: 50% in (+/+) vs. 7.1%"}]}
{"chain_id": "chain_000044", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC12308240", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC12308240, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with increased likelihood of Cardiotoxicity when treated with daunorubicin or doxorubicin in children with Neoplasms as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Contradicted.**\n\nThe paper identifies *ABCC5* rs7627754 as a **cardioprotective** variant, where the A allele is associated with **higher** LVEF (pooled MD 7.39%) and **higher** FS (pooled MD 5.04%) \u2014 meaning better cardiac function, not worse. Therefore, the A allele is associated with a **decreased** likelihood of cardiotoxicity, not an increased likelihood. The claim that allele A is associated with **increased** likelihood of cardiotoxicity compared to allele C is contradicted by the findings."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs17583889 and daunorubicin, doxorubicin in Other:Neoplasms (PMCID PMC12308240), what OR was reported?", "answer": "1.84", "response": "The pooled OR reported for *HNMT* rs17583889 in the meta-analysis was **1.84** (95% CI 1.34\u20132.52)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "**True**\n\nThe 95% confidence interval for the pooled OR of *HNMT* rs17583889 was 1.34\u20132.52, which entirely excludes the null value of 1.0."}]}
{"chain_id": "chain_000045", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4519434", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4519434, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased risk of Heroin Dependence due to heroin as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Contradicted.**\n\nThe paper finds that the **rs3778150-C allele** is associated with **increased** heroin addiction risk (meta-analysis P=4.3\u00d710\u207b\u2078), with odds ratios consistently above 1.0 across all cohorts. This means the C allele (minor allele) confers increased risk, and the T allele (major allele) would be the reference/lower-risk allele. The claim states the opposite \u2014 that T is the risk allele compared to C \u2014 which is contradicted by the findings."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**\n\nThe study represents a clinical association, as it tests SNP associations with heroin addiction in case-control cohorts (Urban Health Study, CIDR\u2013Gelernter Study, and Australian Heroin Dependence Study) totaling 16,729 participants, using logistic regression and meta-analysis to identify genetic variants associated with disease risk."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs511435 and heroin in Toxicity (PMCID PMC4519434), what OR was reported?", "answer": "1.2", "response": "Based on the data in Table 3 of the paper, multiple ORs were reported for rs511435 across different cohorts:\n\n- **Urban Health Study, African Americans:** OR = 1.10 (95% CI: 0.97\u20131.23)\n- **Urban Health Study, European Americans:** OR = 1.25 (95% CI: 1.09\u20131.43)\n- **CIDR \u2013 Gelernter Study, African Americans:** OR = 1.20 (95% CI: 0.93\u20131.59)\n- **Australian Heroin Dependence Study:** OR = 1.16 (95% CI: 1.05\u20131.29)\n\nNo single summary OR from the meta-analysis was explicitly reported for rs511435; only the meta-analysis **P value of 3.0\u00d710\u207b\u2076** was provided. The individual cohort ORs ranged from **1.10 to 1.25**, all indicating that the minor allele (T) was associated with increased heroin addiction risk."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "**False**\n\nNot all confidence intervals exclude the null value of 1.0. Specifically:\n\n- Urban Health Study, African Americans: OR = 1.10 (95% CI: **0.97**\u20131.23) \u2014 includes 1.0\n- CIDR \u2013 Gelernter Study, African Americans: OR = 1.20 (95% CI: **0.93**\u20131.59) \u2014 includes 1.0\n\nWhile the other two cohorts' confidence intervals do exclude 1.0 (European Americans: 1.09\u20131.43; Australian: 1.05\u20131.29), since not all reported confidence intervals exclude the null value, the answer is **false**."}]}
{"chain_id": "chain_000046", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC6773496", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC6773496, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Contradicted**\n\nThe paper found that the rs1042714 C-allele in *ADRB2* **is** significantly associated with heart rate response to both atenolol and metoprolol. Specifically, C-allele carriers had a better heart rate-lowering response to \u03b2-blockers compared to G-allele carriers (meta-analysis \u03b2 = \u22120.95 bpm, P = 3\u00d710\u207b\u2074). Therefore, the claim that allele C is *not* associated with response to atenolol or metoprolol is contradicted by the findings."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**\n\nThe study is based on genetic association analyses using clinical trial data (PEAR, PEAR-2, and INVEST) examining the relationship between SNP genotypes and heart rate response to \u03b2-blockers in hypertensive patient cohorts. This represents observational clinical association evidence, not functional assay evidence."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs1801253 and atenolol, metoprolol in Other:Tachycardia (PMCID PMC6773496)?", "answer": 459, "response": "Based on the paper, the total number of participants included in the study of rs1801253 across the three trials was **2,526**, broken down as follows:\n\n- **PEAR** (atenolol): 757 participants (459 whites + 298 blacks)\n- **PEAR-2** (metoprolol): 368 participants (200 whites + 168 blacks)\n- **INVEST** (atenolol): 1,401 participants (555 whites + 176 blacks + 670 Hispanics)\n\n**Total: 757 + 368 + 1,401 = 2,526**"}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "**True**\n\nThe total sample size of 2,526 participants far exceeds the minimum threshold of N \u2265 30."}]}
{"chain_id": "chain_000047", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC2042718", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC2042718, is the following pharmacogenomic claim supported or contradicted: CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*17. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported.**\n\nThe paper reports that the CYP2D6*17 allele is \"strongly associated with lower capacity for debrisoquine hydroxylation.\" The subject homozygous for CYP2D6*17 (i.e., *17/*17) had a high metabolic ratio of 10.5 (indicating diminished metabolism), whereas subjects carrying one or no copies of *17 (such as *1/*1, *1/*2, or *1/*17 genotypes) would be expected to have lower metabolic ratios (higher metabolic activity). This is consistent with the claim that CYP2D6 *17/*17 is associated with decreased debrisoquine metabolism compared to the combined *1/*1 + *1/*2 + *1/*17 group."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**\n\nThe evidence is based on the association between CYP2D6*17 genotype and debrisoquine metabolic ratios measured in vivo in a population of Zimbabwean Shona subjects (phenotyping via urinary metabolic ratios after debrisoquine administration), rather than an in vitro functional assay of enzyme activity. This represents a clinical genotype-phenotype association study."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of CYP2D6*1, CYP2D6*2, CYP2D6*17 and debrisoquine in Metabolism/PK (PMCID PMC2042718), what p-value was reported for this association?", "answer": "< 0.001", "response": "The paper does not report a specific p-value for this association. The full text is only available as a PDF, and based on the abstract, the authors state that the CYP2D6*17 allele was \"strongly associated with lower capacity for debrisoquine hydroxylation,\" but no explicit p-value is provided in the available text."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": true, "response": "Based on the available information, the paper does not report a specific p-value, so it is not possible to determine whether the association would remain significant at alpha = 0.01. However, given that the authors describe the association as \"strongly associated,\" it is likely significant, but without the exact p-value from the full text, a definitive answer cannot be confirmed.\n\n**False** \u2014 because without a reported p-value, we cannot confirm significance at the alpha = 0.01 threshold."}]}
{"chain_id": "chain_000048", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5354739", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5354739, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased concentrations of methotrexate in children with as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported**\n\nThe paper reports that for **ABCB1 rs9282564** (allele A/G, where the wild-type is A and the variant creates a T>C exchange at position 61), patients carrying the variant allele (C) had higher AUC\u2080\u208b\u2084\u2088 values (OR = 4.2, p = 0.04) and higher peak MTX concentrations (OR = 8.8, p = 0.02) compared to patients with the homozygous wild-type (TT) genotype. The paper explicitly states: \"For ABCB1 rs9282564, the AUC\u2080\u208b\u2084\u2088 of the concentration\u2013time curve and the peak concentration were higher in patients with the variant allele, compared with patients with the homozygous TT genotype.\"\n\nThis supports the claim that the C allele is associated with increased methotrexate concentrations compared to the T allele in children with osteosarcoma."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**\n\nThe study analyzes correlations between genetic polymorphisms (SNPs) and clinical pharmacokinetic parameters (AUC\u2080\u208b\u2084\u2088, peak MTX levels) and toxicity outcomes in a cohort of 59 osteosarcoma patients treated with high-dose methotrexate. This is an observational pharmacogenomic association study using patient clinical data, not a functional assay performed in a laboratory setting (e.g., cell lines, enzyme activity measurements, or reporter gene assays)."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs9282564 and methotrexate in Metabolism/PK (PMCID PMC5354739)?", "answer": 59, "response": "**59**\n\nThe study population consisted of 59 children diagnosed with osteosarcoma, and 551 MTX blocks across these 59 patients were analyzed. The genotyping and association analyses, including for ABCB1 rs9282564 and its relationship with methotrexate pharmacokinetic parameters, were performed on this entire cohort of 59 patients."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "**true**\n\nThe study included 59 patients, which exceeds the minimum threshold of N \u2265 30 for study cases."}]}
{"chain_id": "chain_000049", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC11758033", "num_turns": 4, "model": "anthropic/claude-opus-4-6", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11758033, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with increased resistance to antiepileptics in people with Epilepsy as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported**\n\nThe paper examines the SCN1A rs121917953 T/A* polymorphism, where the relevant alleles are T (wild-type) and A (mutant). The claim refers to allele A vs. allele G. Since allele G is not one of the alleles studied at this locus (the alleles are T and A), the paper provides no evidence that allele A is associated with increased resistance compared to allele **G** specifically. The paper's findings concern the AT genotype vs. TT genotype, not A vs. G. In the absence of any data involving allele G, the claim that \"allele A is not associated with increased resistance compared to allele G\" is not contradicted by the paper's findings.\n\nTherefore, the answer is: **supported**."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "**clinical_association**\n\nThe study is an observational, case-control genetic association study comparing genotype distributions of SCN1A polymorphisms between drug-resistant and drug-responsive epilepsy patients, using chi-square tests, Fisher's exact test, and logistic regression to assess associations. It does not involve any functional experiments (e.g., electrophysiology, cell-based assays, or protein expression studies). Therefore, this represents a **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs121918623 and antiepileptics in Other:Epilepsy (PMCID PMC11758033), what p-value was reported for this association?", "answer": "= 1", "response": "The reported p-value for the association between SCN1A rs121918623 C/T* (T875M) polymorphism and drug resistance was **1.00** (Table 2), indicating no significant difference in genotype distribution between the drug-resistant and drug-responsive groups."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "**false**\n\nThe p-value of 1.00 is far above the significance threshold of 0.05, so the finding is not statistically significant."}]}
